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Objectives: Plasma microRNAs are considered potential diagnostic biomarkers for 
endometriosis. Increasing evidence has shown that a huge number of miRNAs are 
abnormally expressed in endometriosis plasma and play irreplaceable roles in 
diagnosis.  
Material and methods: The aim of our study was to identify the differential 
expression of circular miRNA by reviewing the PubMed, ScienceDirect, and 
Cochrane databases between normal women and women with endometriosis and 
analyzing the miRNA data downloaded from the GEO database.  
Results: Because of the differential miRNA expression in this review, we evaluated 
the diagnostic values of the differentially expressed miRNAs, particularly during the 
menstrual phases. According to the cut-off criteria with |log 2 FC| > 1.0 and P < 0.05, 
36 differentially expressed miRNAs were identified, including 13 upregulated 
miRNAs and 23 downregulated miRNAs. We developed miR-155, miR-574, miR-23a, 
and miR-520d via a Venn diagram. Functional enrichment analysis considered that 
the target miRNAs might be involved in various pathways related to endometriosis, 
including neurotrophin, Hippo, oocyte meiosis, ubiquitin mediated proteolysis, 
HTLV-Infection, FoxO, and Rap1 signaling pathways. CTNNB1, MYC, and ES R1 
of transcription factors were related to the differentially expressed miRNAs.  
Conclusions: In summary, our study suggested that a four-miRNA could be included 
as a prognostic marker in endometriosis. 
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INTRODUCTION  
MicroRNAs (miRNAs) are composed of 21–23 nucleotides. miRNAs have the 
characteristics of high conservation, timing, and tissue specificity. miRNAs are stable 
in serum and may be used as non-invasive diagnostic indicators of diseases [1]. Two 
small non-coded RNAs, namely, Lenin4 and elet-7, which have been recognized as 
being related to various human diseases, were found in Caenorhabditis elegans for the 
first time by Lee in 1993 [2, 3]. Global expression profiling studies have identified 
hundreds of misaligned miRNAs in several diseases. miRNAs are involved in a 
number of steps, such as inclusion, addition, transfer out of the nucleus, processing in 
the fine cytoplasm, and translation or stimulation [4]. 
miRNAs mature by not fully binding to the 3' end of the non-coding region of the 
target gene, inhibition of their translation, or binding to RNA silent complexes 
composed of multiple proteins. Target gene expression can be suppressed by 
completely binding to the non-coding region of the target gene 3' [5, 6]. It is important 
that miRNA can target multiple mRNA expressions, and one mRNA can be regulated 
by multiple miRNAs at the same time through this complex post-transcription 
regulatory network [7, 8]. miRNA is involved in almost all pathophysiological 
processes in the body. To date, more than 1,881 miRNA precursors, encoding more 
than 2,500 miRNAs, have described as mature miRNA in humans. With the increased 
understanding of the mechanism of action of miRNAs and the study of the biogenesis, 
function, role, and characterization of miRNA, candidate biomarkers for many 
diseases have emerged, such as cancer, coronary artery disease, and gynecological 
diseases, including endometriosis [9–13]. Therefore, miRNAs have substantial 
potential as promising markers for diagnosis, prognosis and personalized targeting. 
Endometriosis (EMS) refers to a common estrogen-dependent chronic disease in the 
endometrium (glands and interstitial substances) that occurs in other parts of the 
uterus and affects nearly 10% of women of childbearing age [14–16]. This disease 
primarily causes pelvic pain and infertility. The prevalence of this disorder is an 
estimated global average of 176 million individuals, in whom the diagnosis is delayed 
by seven years, and the mean diagnostic age is 32.5–36.4 years, depending on the 
research population [17]. Although significant progress has been made in the study of 
the etiology and pathogenesis of EMS, unfortunately, compared to other chronic 
diseases, it is difficult to diagnose, and the diagnosis of EMS is often delayed because 
there are currently no accurate, accessible and non-invasive diagnostic tools. Early 
diagnosis and treatment of EMS remain difficult. Therefore, it is urgent to further 
explore the etiology and pathogenesis of EMS to identify specific and sensitive 
detection indicators and treatment targets and provide new ideas and strategies for 
early clinical diagnosis and treatment [18]. In several studies, a specific miRNA has 
been identified as a potential biomarker of the disease. These and other miRNAs have 
been associated with target genes and functional pathways in the disease-specific 
pathophysiology. The occurrence of endometriosis involves various factors, such as 
hormones, inflammatory factors, and hypoxic microenvironments. In recent years, 
studies have shown that tiny RNA also plays an important role in the development of 
endometriosis. There are differences in the expression of miRNA between ectopic 
endometrial tissue cells and normal tissue cells. These differences in the expression of 
miRNA may be related to the occurrence and development of EMS. The expression 
pattern of miRNA in the endometrium in endometriosis is based on patients and 
control women as well as different individuals who have endometriosis. miRNA may 
be an attractive candidate for new diagnostic markers and treatment interventions for 
endometriosis. These small non-coding molecules have become attractive candidates 
as new biomarkers for early non-invasive diagnosis [19–22]. Study of this disease 
may lead to valuable benefits for patients by reducing the recurrence rates in terms of 
prognosis and improvements. 
In this study, a systematic review was conducted of the key serum miRNAs 
predicted for endometriosis diagnosis. GEO (Gene expression omnibus) is a gene 
expression database created and maintained by the NCBI (National Biotechnology 
Information Center of the United States). The purpose of this study is to identify 
miRNA data downloaded from the GEO database to determine serum differences 
between normal women and patients with endometriosis. In miRNA high-throughput 
analysis, miRNA target genes are shown to be differentially expressed and their 
function is annotated, and a miRNA feature that can effectively diagnose 
endometriosis is constructed. In addition, the TFactS database was analyzed using 
analytical transcription factors. This study shows the importance of miRNA in the 
diagnosis of endometriosis. 
 
MATERIAL AND METHODS 
 A systematic review was conducted of all the pertinent studies that were 
identified in the electronic PubMed, ScienceDirect, and the Cochrane Central Register 
of Controlled Trials (CENTRAL) databases that examined plasma microRNAs as 
potential diagnostic biomarkers for endometriosis from 1966 to January 2019. The 
search strategy included the terms miRNA, microRNA, circular, blood, serum, and 
plasma. The search was concluded by 1) perusal of the reference sections of all 
relevant studies in English and 2) a manual search of the key journals and abstracts 
from the major annual meetings in the fields of endocrinology and obstetrics and 
gynecology. Articles were excluded from the analysis that lacked adequate 
disease-matched control groups. The control groups consisted of women without 
endometriosis. 
 
Screening of the endometriosis miRNA expression dataset 
The Series Matrix file of GSE46735 was downloaded from the GEO 
(http://www.ncbi.nlm.nih.gov/geo/) database. The inclusion criteria were as follows: 1) 
Diagnosis of endometriosis and a normal female control group; 2) sample sequencing 
data and clinical information of miRNA; and 3) processed bold parts in the properties 
of natural cells. The platforms included GPL 15634 (Applied Biosystems Human 
TaqMan Low Density Array (TLDA, v2 .0, Card A)) and GPL 15647 (Applied Life, 
dispensers TaunqMan Dense). The datasets of GSE46735 were used to recalibrate the 
relationship between control women and women with quiet division endometriosis (n 
= 8 in each group). Each programmed soft space in the early portfolio included the 
public and personal spaces of the natural class (n = 47 total spaces). The better case is 
better than the better. RNA was made available to study the identified microRNAs. 
miRNA sequencing data were processed using R language packets. The difference 
between endometriosis and normal female blood samples expressed by miRNAs was 
analyzed by Lima packets in R. Multiples in individual expression (FCs) were used to 
calculate miRNA and express miRNA considerations and GT with |log2 FC| > 1.0 and 
p < 0.05. Importantly, differential expression of miRNA at different stages of the 
menstrual cycle was associated with the diagnosis of endometriosis. Differentiated 
expression of the miRNA spectrum was normalized by log2 conversion. We used 
FunRich (http://www.Funrich.org) to obtain the overlapping differential expression of 
miRNA among GSE46735. A Vern diagram and volcano map were also constructed 
by FunRich. We used Heml 1.0 (http://hemi.biocuckoo.org/down.php) to obtain the 
differential expression of miRNA among GSE 46735. A heatmap was also constructed 
by Heml. 
 
Prediction of the functional enrichment of microRNA target genes in 
endometriosis serum 
 Identification of miR target genes was performed with Targetscan 
(http://www.targetscan.org/), miRanda (http://miranda.org.uk), miRDB 
(http://www.mirdb.org/mirdb/), Pictar (https://pictar.mdc-berlin.de), miRWalk 
(http://zmf.umm.uni-heidelberg.de/apps/zmf/mirwalk2/), and RNA22 
(http://cbcsrv.watson.ibm.com/rna22.html/) online analysis tools. To improve the 
reliability of the bioinformatic analysis, a Venn diagram was used to identify 
overlapping target genes. Then, The Date for Annotation, Visualization and Intrusion 
analyze the overlapping gene bioinformatic tool (DAVID) (https://david.ncifcrf.gov/) 
was used. DAVID is the web-based, online and bioinformatic tool designed to provide 
investigators with a complete series of functional annotation tools to identify 
biological mechanisms associated with numerous genes or proteins. GO (Gene 
Ontogirl) and KEGG (Kyoto Engineering of Genes and Genomes) pathway events 
were analyzed for particular genes. A P-value < 0.05 was set as the cut-off for 
significance. 
Analysis of the regulation of miRNA targeting in endometriosis serum was used 
to determine up- and downregulation of miRNA (Essaghir et al.) using the TFactS 
database (2010) (http://www.tfacts.org/). Only four indicators (P-value, Q-value, 
E-value, and FDR) were used in advance to indicate that a value which was less than 
0.05 was considered a reliable transcription factor scope. State on translation factors 
(TF) of target DEMs of up and down-protected miRNA regulated objects where we 
must go to the special study. 
 
RESULTS 
 The electronic search strategy identified 160 potentially relevant articles 
(PubMed, 136; ScienceDirect, 24; and Cochran Library, 0), which filtered articles by 
the title, summary, full text, or a combination of these factors. Of these 160 articles, 
84 articles were excluded because of not meeting the inclusion criteria after reading 
the abstracts. The full studies of the remaining 76 studies, which focused on miRNAs 
used in the diagnosis of endometriosis, were then carefully read. An additional 65 
articles were excluded because the sample originated from peritoneal fluid or urine. 
We excluded trials as follows: data on the diagnosis of endometriosis via a blood test 
identifying microRNAs were not available from the papers and could not be obtained 
from the investigators by e-mail contact and the microRNA detection method used 
reverse transcriptase quantitative real-time PCR. Eleven studies that investigated the 
role of miRNA expression changes as blood biomarkers in endometriosis samples 
were included. Eleven studies analyzed the expression of miRNAs by comparing 
endometriosis cases vs healthy controls [19, 21–31]. A total of 472 endometriosis 
serum samples and 357 normal corresponding serum samples were collected (some 
articles studied serum and some studies studied plasma; for simplicity, we used serum 
instead of serum/plasma). The subjects’ age in the studies ranged from 26 to 53 years 
old. Table 1 summarizes the quality of the trials included in the review. 
By summarizing 11 studies that studied the difference in the expression of 
miRNA in peripheral blood between endometriosis patients and normal individuals, 
the expression of miRNA was obtained, and the increased expressions included： 
miRNA-365, -125b, -150, -342, -143, -145, -500a, -451a, -18a, -154, -196b, -378a, 
-33a, -199a, -122, -4645, -636, -24-2, -3127, -185, -542, -502, -296, -550a, -424, 
-451a, -16, -191, -195, -1978, -1979, -4284, -1973, and -1974; the decreased 
expressions included：miRNA-let7，-135a, -200a, -141, -363, -6755, -145, -141, -542, 
-9, -889,-432, -1381, -410, -584, -99b, -127, -30c, -215, and -17. Quantitative 
real-time polymerase chain reaction detected the expression in blood and peritoneal 
fluid (PF) samples for miR-122 and miR-199a, and serum miR-122 and miR-199a 
detected endometriosis with a sensitivity of 95.6 and 100.0 and specificity of 91.4 and 
100, respectively. MiR-199a (p < 0.05) and miR-122 could be used to distinguish 
between severe and mild endometriosis. MiR-199a was closely related to pelvic 
adhesion and lesions (p < 0.05) and was also related to hormone mediated signaling 
pathways. Moreover, it was confirmed that the best combinations of miR-199a, 
miR-122, miR-145 and miR-542-3p were reliable in terms of sensitivity and 
specificity, and the tested feature lines (Receiver Opera Charitable Curve, ROC) 
Under the Curve Area (Area Under Curve, AUC) was 0.994 (95% CI: 0.984–1.000). 
In addition, the AUC associated with miR-17-5p, miR-20a, and miR-22 was 0.9 (95% 
CI: 0.8–1.0). At the same time, the combination of serum le-7b, 7D and 7f during the 
proliferation period could be used as a diagnostic marker for endometriosis according 
to the differential expression of circulating miRNA between the endometriosis and 
control groups. The level of miRNA varied with the time of blood collection, and 
miR-200a and miR-141 have potential as new non-invasive biomarkers of 
endometriosis. In addition, the plasma levels of miR-200a, miR-200b and miR-141 
varied with the sampling time; thus, the sampling time is critical. The specificity and 
sensitivity of plasma miR-17-5p, miR-20a and miR-22 in the diagnosis of phase III/IV 
endometriosis were 90.0 and 70.0, respectively [19]. 
 
2 GEO analyses 
In the present study, 242 differentially expressed miRNAs in GSE46735 were 
identified in the plasma of endometriosis samples compared to control samples. 
Among the differentially expressed miRNAs, 124 miRNAs were upregulated, while 
118 miRNAs were downregulated. The hierarchical clustering heat map is shown in 
Figure 1, and the volcano map is shown in Figure 2. The identified miRNAs were 
well distinguished from differentially expressed miRNAs. 
Has-miR-155-5p, hsa-miR-128-3p, hsa-miR-1-3p, and hsa-miR-532-5p of the 
upregulated differentially expressed miRNAs (LogFC > 1, P < 0.05) and 
hsa-miR-574-3p, hsa-miR-23a-3p, hsa-miR-520d-5p, hsa-miR-433-3p, 
hsa-miR-485-5p, and hsa-miR-122-5p of the downregulated differentially expressed 
miRNAs (LogFC < –1, P < 0.05) were significantly different. With respect to patients 
who provided blood samples in the early proliferative, late proliferative and mid luteal 
phases of the menstrual cycle (n = 47 total plasma samples), the cycle phase was 
verified according to the hormonal profile. RNA was extracted from each sample, and 
the expression of microRNAs was assessed using TaqMan Low Density Human 
miRNA arrays. Has-miR-155, hsa-miR-218, hsa-miR-301b, hsa-miR-128, 
hsa-miR-532-5p, hsa-miR-22, hsa-miR-1, hsa-miR-339-5p, and hsa-miR-143 in early 
proliferation; has-miR-155, hsa-miR-218, hsa-miR-532-5p, hsa-miR-22, hsa-miR-1, 
hsa-miR-339-5p, hsa-miR-331-5p and hsa-miR-362-3p in late proliferation; and 
has-miR-155, hsa-miR-218, hsa-miR-301b, hsa-miR-128, hsa-miR-133a, and 
hsa-miR-143 in the mid luteal phase were upregulated and differentially expressed 
(LogFC > 1, P < 0.05). Has-miR-574-3p, hsa-miR-23a, hsa-miR-500, hsa-miR-98, 
hsa-miR-7f, hsa-miR-451, hsa-miR-122, hsa-miR-520d-5p, hsa-miR-15a and 
hsa-miR-409-5p in early proliferation, hsa-miR-574-3p, hsa-miR-23a-3p, hsa-miR-98, 
hsa-miR-122, hsa-miR-874, hsa-miR-381, hsa-miR-520d-5p, hsa-miR-452, 
hsa-miR-369-3p, hsa-miR-224, hsa-miR-502-5p, hsa-miR-320, hsa-miR-433 and 
hsa-miR-23b in late proliferation and has-miR-574-3p, hsa-miR-382, hsa-miR-23a, 
hsa-miR-10b, hsa-miR-485-5p, hsa-miR-520d-5p, hsa-miR-433, hsa-miR-452, 
hsa-miR-130b and hsa-miR-874 in the mid luteal phase were downregulated and 
differentially expressed (LogFC < –1, P < 0.05) and were significantly different. The 
consistently upregulated and downregulated genes in independent cohorts in all three 
phases were identified using Venn analysis, and a Venn diagram was generated by 
FunRich (Fig. 3). As a result, we identified has-miR-155-5p as having unregulated 
expression and hsa-miR-574-3p, hsa-miR-23a-3p, and hsa-miR-520d-5p as having 
downregulated expression.  
 
Three Target prediction and function analysis 
The target genes of four miRNAs were predicted using the TargetScan, miRDB, 
RNA22, miRWalk and miRanda online analysis tools. Thirty-nine overlapping genes 
of miR-155-5p, 4 overlapping genes of miR-574-3p, 70 overlapping genes of 
miR-23a-3p, and 107 overlapping genes of miR-520d-5p were identified. Enrichment 
analysis of the target genes was subsequently performed to elucidate the biological 
function of the consensus target genes.  
The biological processes (BP) were mainly enriched in axon guidance, 
peptidyl-tyrosine phosphorylation, negative regulation of an extrinsic apoptotic 
signaling pathway, positive regulation of cell migration, positive regulation of 
transcription, liver development, transmembrane receptor protein tyrosine kinase 
signaling pathway, positive regulation of transcription from RNA polymerase II 
promoter, retinal ganglion cell axon guidance, and negative regulation of transcription 
from RNA polymerase II promoter (Fig. 4-1). The cellular components (CC) were 
significantly enriched in the cell-cell adherens junction, transcriptional repressor 
complex, cell surface, protein-DNA complex, Golgi membrane, cytoplasm, cytosol, 
nucleus, nucleoplasm, and perinuclear region of cytoplasm (Fig. 4-2). The KEGG 
pathways that were primarily significantly enriched were the neurotrophin signaling 
pathway, hippo signaling pathway, oocyte meiosis, ubiquitin mediated proteolysis, 
HTLV-Infection, FoxO signaling pathway, Rap1 signaling pathway, pathways in 
cancer, signaling pathways regulating pluripotency of stem cells, and osteoclast 
differentiation (Fig. 4-3). In addition, the molecular functions (MF) were mainly 
enriched in ubiquitin protein ligase binding, insulin-like growth factor receptor 
binding, chromatin binding, ubiquitin protein ligase activity, SMAD binding, 
transcription corepressor activity, transcriptional repressor activity, protein binding, 
and RNA polymerase II core promoter proximal region sequence-specific DNA 
binding (Fig. 4-4). 
 
Four Analysis of the transcription factors (TFs) of target genes 
The corresponding TFs were analyzed and compared. The results showed that 
there were 61 TFs corresponding to the target. Among them, 56 genes correspond to 
upregulated relating TFs and 17 genes correspond to downregulated relating TFs. 
Comparative analysis suggested that of the 61 TFs, 12 TFs were shared between the 
two target genes, accounting for 19.67% of the total TFs. In addition, the TFs 
corresponding to the regulation of miRNA target genes showed high specificity, 
consistent with the results of the GO analysis, and enriched the regulation of miRNA 
target genes during the regulation of transcription. According to the results of the 
analysis, the main TFs with credibility E values and cross ratios were not more than 
0.05, and only the TFs CTNNB1, MYC, and ES R1 had a hard cross rate. 
 
DISCUSSION 
Endometriosis is the main cause of pelvic pain and low fertility. However, it is 
difficult for the diagnosis of endometriosis, and there is no clear diagnostic biomarker. 
Laparoscopy is currently the gold standard for the endometriosis diagnosis; however, 
it is traumatic. Many clinicians evaluate a series of clinical symptoms of 
endometriosis prior to seeking a definitive diagnosis by laparoscopy. Moreover, 
experimental treatment drugs have significant side effects and are typically not 
completely eradicated [31, 32]. At the same time, 70–75% of visually diagnosed 
lesions are confirmed histologically in laparoscopy, thus hindering their widespread 
use [33]. In addition, CA125 is only 21–50% sensitive for the diagnosis of 
endometriosis. Therefore, there is a need to develop a non-invasive diagnostic test for 
endometriosis. In recent years, studies on miRNAs have shown that their expression 
levels are closely related to the occurrence, development and metastasis of EMS; thus, 
it miRNAs are expected to be non-invasive diagnostic markers for EMS. 
miRNA achieves the regulation of EMS through its regulation [34]. Using TaqMan 
microRNA chips to detect changes in serum miRNA expression levels in EMS 
patients and healthy control groups, studies showed that miR-199 and miR-122 were 
increased in the serum of EMS patients compared to healthy control groups [24]. 
miR-141, miR-9, MiR-145, and miR-542-3p were downregulated, and miR-199 and 
miR-122 could be used to distinguish between severe and mild EMS patients. In 
addition, the area under the ROC curve measured jointly by miR-199, miR-122, 
miR-145 and miR-542-3p was 0.994, and the sensitivity and specificity were 93.22% 
and 96.00%, respectively. It was proven that the combined detection of miR-199, 
miR-122, miR-145 and miR-542-3p as non-invasive biomarkers of EMS had 
significant diagnostic significance. At the same time, it was found that 27 miRNAs 
were differentially expressed in the serum of EMS patients compared to the healthy 
control group using TaqMan microRNA chips [19]. After testing with Real-time PCR, 
it was found that miR-17-5p, miR-20a and miR-22 showed significant downward 
expression, indicating that these miRNAs can be used as serum markers to diagnose 
endometriosis. EMS is characterized by the growth of the endometrium outside the 
endometrium. This process is closely related to factors such as vascular endothelial 
growth factor-A, which regulates angiogenesis, and thrombin-sensitive protein, 
miR-222, and miR-17-5p, which regulate the expression of angiogenic factors and 
play important roles in the pathogenesis of EMS. MiR-199a can inhibit the invasion 
of endometrial stromal cells by inhibiting the IKKβ/NF-κB signaling pathway and 
decreasing IL-8 expression, and it can be used as a serum marker for metastasis in 
EMS patients [36, 37]. Therefore, circulating miRNA can be used as a biomarker for 
the early diagnosis of small and mild endometriosis.  
Because of the differential expression of miRNAs in the review, we downloaded 
a dataset from the GEO database to validate the exact plasma miRNA levels. 
Unexpectedly, we found that miR-155, miR-128, miR-1 and miR-532 of the 
upregulated miRNAs and miR-574, miR-23a, miR-520d, miR-433, miR-485 and 
miR-122 of the downregulated miRNAs were differentially significantly expressed 
and associated with the diagnosis of endometriosis patients in the present study. With 
respect to the phases of the menstrual cycle, we found that miR-155, which 
upregulated miRNA expression, and miR-574, miR-23a, and miR-520d, which 
downregulated miRNAs expression, could be used as a multi-marker-based model to 
provide more powerful information for the prediction of EMS in patients. When it is 
performed enrichment analysis of the four-miRNAs for the prediction and function 
analyses of biological processes, cellular components, KEGG pathways, and 
molecular function. Furthermore, we also assessed the miRNA target genes during the 
regulation of transcription. The results of the functional enrichment analysis implied 
that the three target genes of miRNAs related to endometriosis might be involved in 
various pathways, including neurotrophin, Hippo, oocyte meiosis, ubiquitin mediated 
proteolysis, HTLV-Infection, FoxO, and Rap1 signaling pathways. Unsurprisingly, 
only the transcription factors CTNNB1, MYC, and ES R1 agreed with this 
conclusion. 
In short, in recent years, with the in-depth study of miRNAs, the different stages 
of disease occurrence and development have been shown to be accompanied by 
changes in miRNA expression, and a deep understanding of miRNAs helps to 
scientifically grasp the internal mechanism of disease occurrence. In addition, miRNA 
expression levels are expected to be important markers for disease diagnosis, 
treatment selection, efficacy evaluation, and prognosis evaluation. In summary, a 
number of miRNAs have been found to be differentially expressed in the plasma of 
women with endometriosis, and the mechanism of serum miRNA dysregulation 
remains unknown. To date, as indicated by the different results from the review and 
microarray datasets, circulating miR-155, miR-574, miR-23a, and miR-520d may be 
powerful biomarkers for diagnosis of endometriosis, accurate chemotherapy and 
targeted therapy; however, additional research is required to determine the 
repeatability and consistency of the results. These findings provide new insights into 
the early diagnosis and detection of endometriosis. 
 
CONCLUSIONS 
Comprehensive analysis of the pooled data provides strong evidence that 
circulating unregulated miR-155 expression and downregulated miR-574, miR-23a, 
and miR-520d expression are significantly associated with the diagnosis of 
endometriosis. Abnormal expression of aberrant miR-155 and low expressions of 
miR-574, miR-23a, and miR-520d may be promising diagnostic biomarkers for 
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Figure 3. The Venn diagram of upregulated and downregulated miRNA in all three 
phases of menstruation 
 
 
Figure 4. Target prediction and function analysis in the target genes of miR-155, 
miR-574, miR-23a, and miR-520d (4-1 — biological processes; 4-2 — cellular 




Table 1. Characteristics of eligible studies considered in the report  
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